Clinical outcomes of switching to lonapegsomatropin from somatropin for treatment of pediatric growth hormone deficiency
Lonapegsomatropin may be a favorable option to reduce injection burden for those with pediatric GHD, though the manufacturer's recommended starting dose of 0.24 mg/kg/week may require individualization. Careful monitoring and dose adjustment based on IGF-1 levels are necessary to maintain safety and efficacy.
Authors
- Iris Gutmark‐Little (ORCID: https://orcid.org/0000-0003-0135-4516)
- Gajanthan Muthuvel (ORCID: https://orcid.org/0000-0001-7101-2357)
- E.T. Coyne (ORCID: https://orcid.org/0009-0004-1082-2275)
Institutions
- Cincinnati Children's Hospital Medical Center (US)
Publication Details
- Journal
- Journal of Pediatric Endocrinology and Metabolism
- Published
- 2025-01-23
- DOI
- https://doi.org/10.1515/jpem-2024-0496
- Citations
- 1
- Primary Topic
- Growth Hormone and Insulin-like Growth Factors
- Type
- article
- Field-Weighted Citation Impact
- 1.29